GlassScriptPhysician profile
Arthur E Nwaubani
NPI 1679748107
$5,014.25
in general payments reported to CMS, 2019-2025
25 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,767 · 2020: $315 · 2021: $520 · 2022: $813 · 2023: $159 · 2024: $222 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,852.14 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $890.61 | 2019-2025 | Qelbree, Qelbree |
| Medtronic, INC. | $477.01 | 2022 | |
| Neurelis, INC. | $355.81 | 2020-2025 | Valtoco |
| Ucb, INC. | $348.36 | 2019-2024 | Briviact |
| Aquestive Therapeutics, INC. | $194.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $183.14 | 2019-2021 | |
| Tris Pharma INC | $122.04 | 2019 | |
| Sk Life Science, INC. | $95.13 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $83.03 | 2023 | Aptiom |
| Novartis Pharmaceuticals Corporation | $46.46 | 2019 | |
| Ironshore Pharmaceuticals INC. | $43.81 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $42.85 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $35.05 | 2019-2021 | |
| Travere Therapeutics, INC. | $30.83 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $26.15 | 2022 | |
| Eisai INC. | $24.50 | 2021 | |
| Immedica Pharma US, INC. | $24.39 | 2023 | |
| Acadia Pharmaceuticals INC | $22.89 | 2025 | Daybue |
| Aprecia Pharmaceuticals, LLC | $21.70 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.49 | 2024 | Zonisade |
| Cranial Technologies, INC | $20.71 | 2022 | |
| Aucta Pharmaceuticals, INC. | $20.31 | 2025 | Motpoly Xr |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2025 | Ajovy |
| Arbor Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Nwaubani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.